» Articles » PMID: 35978413

The CORE-KDT Study: a Mixed Methods Protocol to Establish Core Outcomes for Refractory Childhood Epilepsy Treated with Ketogenic Diet Therapy

Overview
Journal Trials
Publisher Biomed Central
Date 2022 Aug 17
PMID 35978413
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A core outcome set defines the minimum outcomes that should be included in clinical trials, audit or practice. The aim being to increase the quality and relevance of research by ensuring consistency in the measurement and reporting of outcomes. Core outcome sets have been developed for a variety of disease states and treatments. However, there is no established set of core outcomes for refractory childhood epilepsy treated with ketogenic diet therapy. This should be developed using a patient-centred approach to ensure the outcomes measured are relevant to patients and clinical practice.

Methods: This is a mixed methods study of four phases to develop a core outcome set for refractory childhood epilepsy treated with ketogenic diet therapy. In phase 1, a systematic scoping review of the literature will establish which outcomes are measured in trials of refractory epilepsy treated with ketogenic diet therapy. In phase 2, qualitative interviews with parents and carers will aim to identify the outcomes of importance to these stakeholders. Phase 3 will see a comprehensive list of outcomes collated from the first two phases, grouped into domains according to an outcome taxonomy. Phase 4 will invite parents, health care professionals and researchers to participate in a two-round Delphi study to rate the importance of the presented outcomes. Following which, the core outcome set will be ratified at a face to face consensus meeting.

Discussion: This study will guide outcome measurement in future studies of childhood epilepsy treated with ketogenic diet therapy and clinical practice through audit and service evaluation.

Citing Articles

The CORE-KDT study: a mixed methods protocol to establish core outcomes for refractory childhood epilepsy treated with ketogenic diet therapy.

Carroll J, Cross J, Hickson M, Williams E, Aldridge V, Collinson A Trials. 2022; 23(1):675.

PMID: 35978413 PMC: 9386954. DOI: 10.1186/s13063-022-06629-7.

References
1.
Schmitt J, Apfelbacher C, Spuls P, Thomas K, Simpson E, Furue M . The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. J Invest Dermatol. 2014; 135(1):24-30. DOI: 10.1038/jid.2014.320. View

2.
MacLennan S, Williamson P, Bekema H, Campbell M, Ramsay C, Ndow J . A core outcome set for localised prostate cancer effectiveness trials. BJU Int. 2017; 120(5B):E64-E79. DOI: 10.1111/bju.13854. View

3.
Young B, Bagley H . Including patients in core outcome set development: issues to consider based on three workshops with around 100 international delegates. Res Involv Engagem. 2018; 2:25. PMC: 5831887. DOI: 10.1186/s40900-016-0039-6. View

4.
Kirkham J, Gorst S, Altman D, Blazeby J, Clarke M, Devane D . Core Outcome Set-STAndards for Reporting: The COS-STAR Statement. PLoS Med. 2016; 13(10):e1002148. PMC: 5068732. DOI: 10.1371/journal.pmed.1002148. View

5.
Gargon E, Gurung B, Medley N, Altman D, Blazeby J, Clarke M . Choosing Important Health Outcomes For Comparative Effectiveness Research: A Systematic Review. Value Health. 2016; 17(7):A435. DOI: 10.1016/j.jval.2014.08.1118. View